**In the Claims:**

This listing of claims will replace all prior versions, and listing, of claims in the Application.

1. (Currently amended) A method for treating dementia [[or a memory disorder]] in a patient in need thereof comprising administering to the patient a therapeutically effective amount of galantamine (I) and a statin (II).

2. (Original) The method of Claim 1 wherein the dementia is dementia as a result of Alzheimer's disease.

3. (Original) The method of Claim 1 wherein the statin (II) is selected from the group comprising simvastatin, pravastatin, lovastatin, fluvastatin, atorvastatin or rosuvastatin, or a therapeutically active acid addition salt form of any of the foregoing, and galantamine (I) is in the form of galantamine hydrobromide (1:1) salt.

4. (Original) The method of Claim 1 wherein the amount of statin (II) is equal to or less than that which is approved in monotherapy with said statin (II).

5. (Original) The method of Claim 1 wherein the amount of galantamine (I) as base is 8, 16 or 24 mg per dosage form.

6. (Currently amended) A product containing as first active ingredient galantamine (I) and as second active ingredient a statin (II), as a combined preparation for simultaneous, separate or sequential use in the treatment of patients suffering from dementia [[or a memory disorder]].

7. (Original) The product of claim 6 wherein the statin (II) is selected from the group comprising simvastatin, pravastatin, lovastatin, fluvastatin, atorvastatin or rosuvastatin, or a therapeutically active acid addition salt form of any of the foregoing, and galantamine (I) is in the form of galantamine hydrobromide (1:1) salt.

8. (Original) The product of claim 6 wherein the amount of statin (II) is equal to or less than that which is approved in monotherapy with said statin (II).

9. (Original) The product of claim 6 wherein the amount of galantamine (I) as base is 8, 16 or 24 mg per dosage form.

10. (Original) A pharmaceutical composition comprising a carrier and as first active ingredient galantamine (I) and as second active ingredient a statin (II).

11. (Currently amended) The composition of claim 10, comprising a carrier and as first active ingredient galantamine (I) and as second active ingredient a statin (II), each in an amount producing a therapeutic effect in patients suffering from dementia [[or a memory disorder]].

12. (Original) The composition of claim 10 wherein the statin (I) is selected from the group comprising simvastatin, pravastatin, lovastatin, fluvastatin, atorvastatin or rosuvastatin, or a therapeutically active acid addition salt form of any of the foregoing, and galantamine is in the form of galantamine hydrobromide (1:1) salt.

13. (Original) The composition of claim 10 wherein the amount of statin (II) is equal to or less than that which is approved in monotherapy with said statin (II).

14. (Original) The composition of claim 10 wherein the amount of galantamine (I) as base is 8, 16 or 24 mg per dosage form.

Claims 15-18 (Canceled)

19. (Previously presented) A process for making a pharmaceutical composition as defined in claim 10 comprising mixing galantamine (I), a statin (II) and a pharmaceutically acceptable carrier.